Curcuma-Based Nutritional Supplement in Patients with Neovascular Age-Related Macular Degeneration

다국어 초록 (Multilingual Abstract)

To investigate effectiveness and safety of a curcumin-based nutritional supplement in neovascular age-related macular degeneration (AMD). We conducted a controlled retrospective study, reviewing the medical records of patients referred to the Eye Center, Humanitas Hospital, Bergamo due to neovascular AMD and treated with antivascular endothelial growth factor (VEGF) intravitreal injections (IVIs) and oral administration of a curcumin-based nutritional supplement vehiculated by enterosoma-I®. We retrospectively collected data of 18 naive patients who received IVI and daily oral nutritional supplement and 24 naive age-matched controls with the same diagnosis undergoing only IVI. All patients underwent a loading-phase of one-per-month IVI for 3 months and then received IVI pro re nata. Median best-corrected visual acuity was significantly improved in treated patients compared with controls (P < .05), while there was no statistical difference in central macular thickness between groups (P > .05). The total number of injections (tIVI) was significantly (P < .05) reduced in the treated group compared with controls. The tIVI in treated group ranged from 3 to 5 with a median of 4 while control group received a tIVI that ranged between 6 and 7 with a median of 7. Treatment with curcumin-based nutritional supplement was safe and effective. Curcumin is a promising adjuvant of anti-VEGF treatment, improves functional outcomes, and prolongs duration.

참고문헌 (Reference)

1 Radomska-les´niewska DM, "Therapeutic potential of curcumin in eye diseases" 44 : 2-4, 2019

2 Davis MD, "The age-related eye disease study severity scale for age-related macular degeneration : AREDS Report No. 17" 123 : 1484-1498, 2006

3 Mitchell P, "Seminar Age-related macular degeneration" 392 : 1147-1159, 2018

4 Lambert NG, "Risk factors and biomarkers of age-related macular degeneration" 54 : 64-102, 2016

5 Subramani M, "Resveratrol reverses the adverse effects of bevacizumab on cultured" 7 : 12242-, 2017

6 Ou WC, "Relationship between visual acuity and retinal thickness during anti-vascular endothelial growth factor therapy for retinal diseases" 180 : 8-17, 2017

7 Wang H, "Regulation of signaling events involved in the pathophysiology of neovascular AMD" 22 : 189-202, 2016

8 Brown DM, "Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration : Two-year results of the ANCHOR study" 116 : 57-65, 2008

9 Berg K, "Ranibizumab or bevacizumab for neovascular age-related macular degeneration according to the lucentis compared to avastin study treat-andextend protocol two-year results" 123 : 51-59, 2016

10 Kaiser PK, "Ranibizumab for neovascular age-related macular degeneration" 355 : 1419-1431, 2006

11 Group CR, "Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration" 119 : 1388-1398, 2012

12 Murata T, "Peroxisome proliferatoractivated receptor-c ligands inhibit choroidal neovascularization" 41 : 2309-2317, 2000

13 Chen M, "Parainflammation, chronic inflammation and age-related macular degeneration" 98 : 713-725, 2016

14 Thanou M, "Oral drug absorption enhancement by chitosan and its derivatives" 52 : 117-126, 2001

15 Yang K, "Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS" 853 : 183-189, 2007

16 Liu W, "Oral bioavailability of curcumin : Problems and advancements" 24 : 694-702, 2016

17 Zuber-Laskawiec K, "Non-responsiveness and tachyphylaxis to anti-vascular endothelial growth factor treatment in naive patients with exudative age-related macular degeneration" 70 : 779-785, 2019

18 Fratter BDS, "New oral delivery system to improve absorption of berberine" 5 : 33-42, 2014

19 Forooghian F, "Investigation of the role of neutralizing antibodies against bevacizumab as mediators of tachyphylaxis" 89 : e206-, 2011

20 Izumi-nagai K, "Inhibition of choroidal neovascularization with an anti-inflammatory carotenoid astaxanthin" 49 : 1679-1685, 2008

21 Paolino D, "Improvement of oral bioavailability of curcumin upon microencapsulation with methacrylic copolymers" 7 : 485-, 2016

22 Polat O, "Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in patients with age-related macular degeneration" 47 : 205-210, 2017

23 Rosenfeld PJ, "Estimating Medicare and patient savings from the use of bevacizumab for the treatment of exudative age-related macular degeneration" 191 : 135-139, 2018

24 Ipar VS, "Enhancing curcumin oral bioavailability through nanoformulations" 44 : 459-480, 2019

25 Meng Y, "Effect of curcumin on aging retinal pigment epithelial cells" 9 : 5337-5344, 2015

26 Tan JSL, "Dietary antioxidants and the long-term incidence of age-related macular degeneration" 115 : 334-341, 2008

27 Woo JM, "Curcumin protects retinal pigment epithelial cells against oxidative stress via induction of heme oxygenase-1 expression and reduction of reactive oxygen" 18 : 901-908, 2012

28 Pescosolido N, "Curcumin : Therapeutical potential in ophthalmology" 80 : 249-254, 2014

29 Ja¨ger R, "Comparative absorption of curcumin formulations" 13 : 11-, 2014

30 Cuomo J, "Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation" 74 : 664-669, 2011

31 Giannaccare G, "Clinical applications of astaxanthin in the treatment of ocular diseases : Emerging insights" 18 : 239-, 2020

32 Piermarocchi S, "Carotenoids in agerelated maculopathy Italian Study(CARMIS) : Two-year results of a randomized study" 22 : 216-225, 2012

33 Li Z, "Astaxanthin protects ARPE-19 cells from oxidative stress via upregulation of Nrf2-regulated phase II enzymes through activation of PI3K/Akt" 19 : 1656-1666, 2013

34 Chakravarthy PU, "Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation : 2-year fi ndings of the IVAN randomised controlled trial" 382 : 1258-1267, 2013

35 Yang S, "A comprehensive review" 10 : 1857-1867, 2016

36 Stohs SJ, "A comparative pharmacokinetic assessment of a novel highly bioavailable curcumin formulation with 95% curcumin : A randomized, double-blind, crossover study" 37 : 51-59, 2018